Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IRIX NYSE:NSPR NASDAQ:NTRB NASDAQ:NVNO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIRIXIRIDEX$1.26-3.1%$1.08$0.78▼$2.14$21.83M0.62192,415 shs23,163 shsNSPRInspireMD$2.39-4.4%$2.42$1.99▼$3.80$76.59M0.6103,653 shs56,922 shsNTRBNutriband$7.13+2.6%$7.92$3.72▼$11.78$77.52M1.1334,632 shs22,030 shsNVNOenVVeno Medical$4.74-5.0%$4.35$2.03▼$5.81$96.04M1.01151,686 shs181,784 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIRIXIRIDEX-3.08%-4.55%+31.24%+9.09%-30.77%NSPRInspireMD-4.40%-14.34%+5.75%-8.08%-16.43%NTRBNutriband+2.59%-1.11%-13.15%+24.65%+35.04%NVNOenVVeno Medical-5.01%+2.82%+19.70%+32.03%-4.63%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationIRIXIRIDEX0.4619 of 5 stars0.04.00.00.00.61.70.0NSPRInspireMD3.6397 of 5 stars3.53.00.00.03.84.20.6NTRBNutriband2.7586 of 5 stars3.55.00.00.00.61.70.6NVNOenVVeno Medical0.3178 of 5 stars0.02.00.00.01.30.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIRIXIRIDEX 0.00N/AN/AN/ANSPRInspireMD 3.00Buy$4.5088.28% UpsideNTRBNutriband 3.00Buy$13.0082.33% UpsideNVNOenVVeno Medical 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest IRIX, NVNO, NTRB, and NSPR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/12/2025NSPRInspireMDPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$4.50 ➝ $4.00(Data available from 8/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIRIXIRIDEX$48.67M0.43N/AN/A$0.13 per share9.69NSPRInspireMD$7.07M10.36N/AN/A$1.83 per share1.31NTRBNutriband$2.14M37.15N/AN/A$0.58 per share12.29NVNOenVVeno MedicalN/AN/AN/AN/A$1.72 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIRIXIRIDEX-$8.91M-$0.43N/A∞N/A-14.61%-290.57%-22.86%8/12/2025 (Estimated)NSPRInspireMD-$19.92M-$0.83N/AN/AN/A-413.96%-69.42%-57.68%N/ANTRBNutriband-$10.48M-$0.90N/AN/AN/A-415.93%-68.25%-60.40%9/2/2025 (Estimated)NVNOenVVeno Medical-$21.82M-$1.20N/AN/AN/AN/A-57.35%-53.49%N/ALatest IRIX, NVNO, NTRB, and NSPR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails9/2/2025N/ANTRBNutriband-$0.17N/AN/AN/A$0.71 millionN/A7/31/2025Q2 2025NVNOenVVeno Medical-$0.28-$0.33-$0.05-$0.33N/AN/A5/30/2025Q1 2026NTRBNutriband-$0.13-$0.12+$0.01-$0.12$0.71 million$0.67 million5/13/2025Q1 2025IRIXIRIDEX-$0.10-$0.10N/A-$0.10$12.10 million$11.90 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIRIXIRIDEXN/AN/AN/AN/AN/ANSPRInspireMDN/AN/AN/AN/AN/ANTRBNutribandN/AN/AN/AN/AN/ANVNOenVVeno MedicalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIRIXIRIDEX4.281.951.27NSPRInspireMDN/A6.396.05NTRBNutriband0.013.713.48NVNOenVVeno MedicalN/A11.8111.81Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIRIXIRIDEX20.10%NSPRInspireMD44.78%NTRBNutriband19.70%NVNOenVVeno Medical34.71%Insider OwnershipCompanyInsider OwnershipIRIXIRIDEX7.40%NSPRInspireMD34.06%NTRBNutriband54.09%NVNOenVVeno Medical16.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIRIXIRIDEX12016.79 million15.55 millionOptionableNSPRInspireMD5030.64 million18.33 millionOptionableNTRBNutriband1011.15 million5.12 millionNot OptionableNVNOenVVeno Medical3019.25 million16.17 millionOptionableIRIX, NVNO, NTRB, and NSPR HeadlinesRecent News About These CompaniesHealth Economic Study Shows That enVVeno Medical's VenoValve(R) Would be a Cost-Effective Treatment Option for Patients with Severe Chronic Venous InsufficiencyAugust 6 at 8:30 AM | accessnewswire.comAenVVeno Medical Participates in a New Virtual Investor “What This Means” Segment to Discuss How President Trump’s Recent CVI Diagnosis May Impact the CompanyAugust 6 at 2:57 AM | desmoinesregister.comDenVVeno Medical Participates in a New Virtual Investor "What This Means" Segment to Discuss How President Trump's Recent CVI Diagnosis May Impact the CompanyAugust 4, 2025 | accessnewswire.comAenVVeno Medical Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateAugust 1, 2025 | accessnewswire.comADauntless Investment Group LLC Purchases Shares of 70,848 enVVeno Medical Corporation (NASDAQ:NVNO)July 29, 2025 | marketbeat.comenVVeno Medical (NVNO) Projected to Post Quarterly Earnings on WednesdayJuly 29, 2025 | americanbankingnews.comenVVeno Medical (NVNO) to Release Earnings on WednesdayJuly 23, 2025 | marketbeat.comenVVeno Medical Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand ConferenceJuly 22, 2025 | indystar.comIenVVeno Medical Participates in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand ConferenceJuly 22, 2025 | accessnewswire.comAEnVVeno Medical Reveals Promising 2-Year Data From VenoValve Clinical TrialJune 7, 2025 | nasdaq.comPositive Interim 2-Year Data from enVVeno Medical’s VenoValve Pivotal Study to be Presented Today at the Society for Vascular Surgery (SVS) 2025 Vascular Annual MeetingJune 7, 2025 | cincinnati.comCPositive Interim 2-Year Data from enVVeno Medical's VenoValve Pivotal Study to be Presented Today at the Society for Vascular Surgery (SVS) 2025 Vascular Annual MeetingJune 6, 2025 | accessnewswire.comAEnVVeno Medical Names Jennifer Bright as CFOMay 19, 2025 | ocbj.comOenVVeno Medical Appoints Jennifer Bright as Chief Financial OfficerMay 19, 2025 | accessnewswire.comAEnVVeno has first-in-human heart valve data, expects FDA decision this yearMay 14, 2025 | massdevice.comThree-Year VenoValve(R) First-in-Human Trial Data Published in the Annals of Vascular SurgeryMay 13, 2025 | accessnewswire.comAenVVeno Medical Reports First Quarter 2025 Financial Results and Reiterates Progress Toward VenoValve FDA Decision Expected in 2H24May 1, 2025 | accessnewswire.comAVenoValve to be Featured During Presentation at the 47th Annual Charing Cross SymposiumApril 23, 2025 | accessnewswire.comAenVVeno Medical Corp appoints CBIZ CPAs as new auditorApril 23, 2025 | investing.comenVVeno Medical to Participate in a Live Virtual Investor Closing Bell SegmentApril 16, 2025 | accessnewswire.comAAnalysis of SAVVE Pivotal Trial Data Presented for enVVeno VenoValveApril 15, 2025 | evtoday.comENew MarketBeat Followers Over TimeMedia Sentiment Over TimeIRIX, NVNO, NTRB, and NSPR Company DescriptionsIRIDEX NASDAQ:IRIX$1.26 -0.04 (-3.08%) Closing price 08/7/2025 03:59 PM EasternExtended Trading$1.30 +0.04 (+3.49%) As of 08/7/2025 05:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. It offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform MicroPulse transscleral laser therapy; G-Probe, which is used in procedures to treat uncontrolled glaucoma; G-Probe and G-Probe Illuminate, which are used in procedures to treat refractory glaucoma; and EndoProbe family of products for use in vitrectomy procedures. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, veterinary practices, and office clinics. It markets its products through direct and independent sales force in the United States, as well as through independent distributors internationally. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California.InspireMD NYSE:NSPR$2.39 -0.11 (-4.40%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$2.46 +0.07 (+2.93%) As of 08/7/2025 06:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.InspireMD, Inc., a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions. InspireMD, Inc. has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.Nutriband NASDAQ:NTRB$7.13 +0.18 (+2.59%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$7.12 -0.01 (-0.21%) As of 08/7/2025 06:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. It has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices; and Kindeva Drug Delivery, L.P. to develop AVERSAL Fentanyl based on its proprietary AVERSAL abuse deterrent transdermal technology. The company was incorporated in 2016 and is headquartered in Orlando, Florida.enVVeno Medical NASDAQ:NVNO$4.74 -0.25 (-5.01%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$4.83 +0.09 (+1.88%) As of 08/7/2025 05:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.enVVeno Medical Corporation (Nasdaq: NVNO) is an medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. The company's lead product, the VenoValve®️, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI). Deep venous CVI occurs when valves inside of the deep veins of the leg become damaged, resulting in insufficient blood being returned to the heart. The malfunctioning vein valves cause blood to flow backwards (reflux) and pool in the lower leg, increasing the pressure within the veins of the leg (venous hypertension). In the most severe cases, CVI can lead to venous ulcers (open skin sores) that become chronic and difficult to heal. The VenoValve is implanted in the femoral vein and works as a replacement venous valve, designed to reduce reflux and venous hypertension, and to restore proper directional blood flow back to the heart. With severe deep venous CVI impacting an estimated 2.4 million people in the U.S., who have no effective treatment options, the VenoValve has received Breakthrough Device Designation from the U.S. Food and Drug Administration, and is currently being evaluated in the SAVVE U.S. clinical trial. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Constellation Energy’s Earnings Beat Signals a New Era AppLovin’s Q2 Miss Spooks Market, But Wall Street Doubles Down Realty Income Rallies Post-Earnings Miss—Here’s What Drove It Don't Mix the Signal for Noise in Super Micro Computer's Earnings Microsoft Stock Gains as Analysts Boost Price Targets Joby Deal Gives Blade New Direction, But Stock Lacks Lift Uber Technologies Is Driving Cash Flow: Ride It Higher for Life How DigitalOcean's Focus Is Fueling Explosive Growth Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
